This Is Why Amicus Therapeutics, Inc. (FOLD) Kept Me Up At Night?

This Is Why Amicus Therapeutics, Inc. (FOLD) Kept Me Up At Night?

This Is Why Amicus Therapeutics, Inc. (FOLD) Kept Me Up At Night?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) stock is presently standing at about $9.96 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 6 analysts covering the company is $12.25, which suggests the stock could still rise over 19 percent. The highest analyst price target is $18.00, which implies a rally of 19 percent. And a quick view of analyst notes show that 3 are rating the stock a buy while 3 rate FOLD a strong buy. There are 1 equity research firms advocating a Hold and 0 consider it Sell.

Robert W. Baird analysts provided their view on Amicus Therapeutics, Inc. (NASDAQ:FOLD) recently. The rating firm issued a Outperform rating to this company in a research note released on Jan 24, 2017. BofA/Merrill analysts disclosed their opinion on Amicus Therapeutics, Inc. (NASDAQ:FOLD) recently. The rating firm gave a Buy rating to this stock in a research note published on May 18, 2016. According to a research note disclosed on Sep 16, 2015, analysts at Chardan Capital Markets have lowered their rating on these shares from Buy to Neutral.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Transactions Roundup

Several insiders were part of recent insider activity for the stock. Its Chief Medical Officer Barth Jay Sold 64,184 company shares for 300,000, in a transaction on Jun 19. Following the transaction, the Chief Medical Officer is left with a stake of 30,000 shares, currently valued at $298,800. Meanwhile, Chief Science Officer Do Hung sold 474,438 shares worth $239,312, through a transaction dated May 19. Following the completion of the transaction, the insider is left with a stake of 29,914 shares, amounting $297,943. FOLD Chief Science Officer Do Hung also sold 504,352 shares, at a stock price of $8.00. This transaction occurred on May 15 totals $239,312. After this transaction, the insider’s stake stands at 29,914 shares, with a market value of $297,943.

Executives hold 1.32 percent of the stock. FMR LLC is one of the biggest insider owners in Amicus Therapeutics, Inc. (NASDAQ:FOLD), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 20,732,355 shares which have current market value of around $206,494,256.PERCEPTIVE ADVISORS LLC is another major inside shareholder in the company. The insider owns 17,296,672 shares as of 03/31/2017, currently worth $172,274,853. BLACKROCK INC. is ranked as third insider holder of the stock. This insider holds 11,967,596 shares with a market value around $119,197,256 as of recent close.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Earnings Outlook

In Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s latest quarter, EPS moved to $-0.39 from $-0.42 in preceding quarter and revenues reached at $4.17M compared to $2.83M. Analysts had expected Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post net income of about $-0.36 per share on $4.16M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in the range of $-0.39 to $-0.33. That is compared with the $-0.4 in EPS it reported during the same period a year ago.

Risk Warning: Investing in digital currencies, stocks, shares and other securities, commodities, currencies and other derivative investment products (e.g. contracts for difference (“CFDs”) is speculative and carries a high level of risk. Each investment is unique and involves unique risks.

CFDs and other derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how an investment works and whether you can afford to take the high risk of losing your money.

Cryptocurrencies can fluctuate widely in prices and are, therefore, not appropriate for all investors. Trading cryptocurrencies is not supervised by any EU regulatory framework. Past performance does not guarantee future results. Any trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Your capital is at risk.

When trading in stocks your capital is at risk.

Past performance is not an indication of future results. Trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Prices may go down as well as up, prices can fluctuate widely, you may be exposed to currency exchange rate fluctuations and you may lose all of or more than the amount you invest. Investing is not suitable for everyone; ensure that you have fully understood the risks and legalities involved. If you are unsure, seek independent financial, legal, tax and/or accounting advice. This website does not provide investment, financial, legal, tax or accounting advice. Some links are affiliate links. For more information please read our full risk warning and disclaimer.